Literature DB >> 21343554

Biology-driven phase II trials: what is the optimal model for molecular selection?

Fabrice Andre1, Suzette Delaloge, Jean-Charles Soria.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21343554     DOI： 10.1200/JCO.2010.31.6877

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Authors:  J Rodon; J C Soria; R Berger; G Batist; A Tsimberidou; C Bresson; J J Lee; E Rubin; A Onn; R L Schilsky; W H Miller; A M Eggermont; J Mendelsohn; V Lazar; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-23       Impact factor: 32.976

Review 3.  Clinical management of breast cancer heterogeneity.

Authors:  Dimitrios Zardavas; Alexandre Irrthum; Charles Swanton; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

Review 4.  The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.

Authors:  Monica Arnedos; Fabrice André; Françoise Farace; Ludovic Lacroix; Benjamin Besse; Caroline Robert; Jean Charles Soria; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2012-03-16       Impact factor: 6.603

5.  Triple-negative breast cancer: are we making headway at least?

Authors:  Monica Arnedos; Celine Bihan; Suzette Delaloge; Fabrice Andre
Journal:  Ther Adv Med Oncol       Date:  2012-07       Impact factor: 8.168

Review 6.  Breast cancer metastasis: issues for the personalization of its prevention and treatment.

Authors:  Natascia Marino; Stephan Woditschka; L Tiffany Reed; Joji Nakayama; Musa Mayer; Maria Wetzel; Patricia S Steeg
Journal:  Am J Pathol       Date:  2013-07-26       Impact factor: 4.307

7.  Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

Authors:  M J Overman; V Morris; B Kee; D Fogelman; L Xiao; C Eng; A Dasari; R Shroff; T Mazard; K Shaw; E Vilar; K Raghav; I Shureiqi; L Liang; G B Mills; R A Wolff; S Hamilton; F Meric-Bernstam; J Abbruzzese; J Morris; D Maru; S Kopetz
Journal:  Ann Oncol       Date:  2016-02-18       Impact factor: 32.976

Review 8.  Clinical application of high-throughput genomic technologies for treatment selection in breast cancer.

Authors:  Aaron R Hansen; Philippe L Bedard
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

9.  Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Authors:  Christine M Lovly; Kimberly Brown Dahlman; Laurel E Fohn; Zengliu Su; Dora Dias-Santagata; Donna J Hicks; Donald Hucks; Elizabeth Berry; Charles Terry; MarKeesa Duke; Yingjun Su; Tammy Sobolik-Delmaire; Ann Richmond; Mark C Kelley; Cindy L Vnencak-Jones; A John Iafrate; Jeffrey Sosman; William Pao
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

Review 10.  Adjuvant chemotherapy.

Authors:  B Glimelius
Journal:  EJC Suppl       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.